Department of Biotechnology, College of Applied Life Science, SARI, Jeju National University, Jeju 63243, Republic of Korea; Subtropical/Tropical Organism Gene Bank, Jeju National University, Jeju 63243, Republic of Korea.
Department of Biotechnology, College of Applied Life Science, SARI, Jeju National University, Jeju 63243, Republic of Korea; Subtropical/Tropical Organism Gene Bank, Jeju National University, Jeju 63243, Republic of Korea.
Phytomedicine. 2019 May;58:152762. doi: 10.1016/j.phymed.2018.11.022. Epub 2018 Nov 20.
We have previously reported the functional anti-cancer effects of the products of enzymatic hydrolysis of Citrus unshiu peel (εCUP) and fermented extraction of Citrus unshiu peel (ƒCUP) in human pancreatic cancer. Despite their different characteristics and effects, the underlying mechanism remains elusive.
In this study, we further demonstrate the impact of ingredient contents of Citrus unshiu peel on the cancer's natural features.
Anti-pancreatic cancer activities following combined treatment of naringenin and hesperetin were demonstrated in vitro and in vivo experiments.
Combined treatment with naringenin and hesperetin inhibited the growth of human pancreatic cancer cells (εCUP mimic condition, p < 0.001 for Miapaca-2 cells) through induction of caspase-3 cleavage compared to separate treatment with naringenin or hesperetin. Combined treatment with naringenin and hesperetin also inhibited the migration (εCUP mimic condition, p < 0.001 for Panc-1 cells) of human pancreatic cancer cells. The εCUP mimic condition had the most effective anti-cancer features; in contrast, which had no inhibitory effect on growth and migration of normal cells (HUVECs and Detroit551 cells). In addition, εCUP mimic condition inhibited the phosphorylation of focal adhesion kinase (FAK) and p38 signaling compared with separate treatment with naringenin or hesperetin. Of note, εCUP mimic condition showed a prominent anti-growth effect (p < 0.001) compared with control or ƒCUP mimic condition in vivo xenograft models.
These results suggest that combined treatment with naringenin and hesperetin might be a promising anti-cancer strategy for pancreatic cancers without eliciting toxicity on normal cells.
我们之前报道过酶解陈皮产物(εCUP)和陈皮发酵提取物(ƒCUP)在人胰腺癌细胞中的抗肿瘤功能。尽管它们的特点和作用不同,但潜在的机制仍不清楚。
本研究进一步证明了陈皮成分含量对肿瘤自然特征的影响。
在体外和体内实验中,研究了橙皮苷和柚皮苷联合治疗对胰腺癌细胞的抗癌活性。
与单独使用橙皮苷或柚皮苷相比,橙皮苷和柚皮苷联合处理可诱导 caspase-3 切割,从而抑制人胰腺癌细胞(εCUP 模拟条件下,Miapaca-2 细胞,p<0.001)的生长。橙皮苷和柚皮苷联合处理还抑制了人胰腺癌细胞的迁移(εCUP 模拟条件下,Panc-1 细胞,p<0.001)。εCUP 模拟条件具有最强的抗癌特征;相反,它对正常细胞(HUVECs 和 Detroit551 细胞)的生长和迁移没有抑制作用。此外,与单独使用橙皮苷或柚皮苷相比,εCUP 模拟条件抑制了粘着斑激酶(FAK)和 p38 信号的磷酸化。值得注意的是,与对照或ƒCUP 模拟条件相比,εCUP 模拟条件在体内异种移植模型中显示出显著的抗生长作用(p<0.001)。
这些结果表明,橙皮苷和柚皮苷联合治疗可能是一种有前途的胰腺癌治疗策略,而不会对正常细胞产生毒性。